Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Comments
Loading...
  • Selecta Biosciences Inc SELB and Ginkgo Bioworks Holdings Inc DNA have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. 
  • The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
  • Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
  • Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
  • Related: Selecta In-Licenses Rights To IgG Protease Platform.
  • Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
DNA Logo
DNAGinkgo Bioworks Holdings Inc
$7.008.43%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum11.35
Growth68.89
Quality-
Value77.02
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: